Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer source : Www.globenewswire.com save search
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K
|
Manufacturing
|
| O: 0.25%
H: 0.0%
C: 0.0%
evx-01 first vaccine cancer trial
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
PVCT 4 | $0.195 -15.0% 56K
|
Manufacturing
|
| O: 0.0%
H: 17.21%
C: 7.19%
pv-10 presentation cancer immunotherapy for meeting
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
MNPR | $0.636 -6.19% -6.6% 33K
|
Health Technology
|
| O: 4.79%
H: 5.3%
C: 3.41%
mnpr-101 cancer for trial advanced
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
PRPH | $5.15 -5.33% -5.63% 99K
|
Health Technology
|
| O: -7.22%
H: 2.98%
C: 1.49%
management test cancer
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -2.03%
H: 2.35%
C: -2.76%
association direct cancer research meeting
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: -3.83%
H: 0.0%
C: 0.0%
breast cancer preclinical for
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
APLM | $0.472 -7.45% -8.05% 170K
|
n/a
|
| O: -2.99%
H: 6.9%
C: 0.0%
association cancer research for meeting
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
MURA | $3.55 -0.56% -0.56% 240K
|
|
| O: -1.2%
H: 1.94%
C: 0.0%
il-18 association cancer research preclinical for meeting il-12
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
STTK | $9.58 -5.43% -5.74% 420K
|
Health Technology
|
| O: -1.11%
H: 9.78%
C: 9.66%
association presentation cancer research preclinical for meeting
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
CMPX | $1.48 -0.67% -0.68% 230K
|
Professional, Scientific, and T...
|
| O: 2.06%
H: 0.0%
C: 0.0%
association tumors cancer research for meeting therapeutics negative
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.96 0.38% 0.38% 790K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
IMRX | $1.8 1.7% 1.67% 520K
|
|
| O: 0.0%
H: 4.72%
C: 3.3%
cancer pancreatic
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
IOBT | $1.47 0.0% 92K
|
|
| O: 1.91%
H: 2.5%
C: 0.63%
io102 biotech cancer
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -3.82%
H: 0.0%
C: -13.49%
mdna113 association cancer research preclinical for meeting
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.